Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
Microbiotica has been established to commercialise ground-breaking research, conducted in the Host-Microbiotica Interactions Laboratory (HMIL) at the Sanger Institute, into the role of the human microbiome in health and disease and its application to medicine. The Sanger Institute teams have made significant breakthroughs in the analysis and understanding of the human microbiome, combining an extensive DNA sequencing capability with novel culturing methods to build a first-in-class gut microbiome culture collection and reference genome library.
Based on the same campus as the Sanger Institute and funded by CIC and IP Group, Microbiotica has been granted unique access to the resources and capabilities of the Sanger Institute in this area. The company intends to use these to gain unparalleled insights into the microbial communities in both healthy and diseased individuals, enabling the identification of specific disease-related bacteria, patient-stratification strategies and novel therapeutics. Microbiotica has also been granted exclusive rights to existing potentially therapeutic bacterial mixes that have shown striking effects in novel models of disease, and which will be progressed into pre-clinical development.